A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
a study on Solid Tumor
Solid Tumor 177Lu-FAP-2286 68Ga-FAP-2286 theranostic FAP-2286 FAP fibroblast activation protein dosimetry CAF cancer-associated fibroblasts Peptide-Targeted Radioligand Therapy PTRT Peptide Receptor RadionuclideTherapy PRRT TRT Targeted radioligand therapy Target radionuclide therapy Lutetium-177 Gallium-68 Neoplasms
Lead Scientist at University of California Health
- Thomas Hope, MD (ucsf)
Thomas Hope, MD, is the Vice Chair of Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee.
- accepting new patients
- Start Date
- Completion Date
- Clovis Oncology, Inc.
- Phase 1/2 Solid Tumor Research Study
- Study Type
- Expecting 170 study participants
- Last Updated